Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Dave Ricks

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

President Donald Trump unveiled a major pricing and coverage deal with drug giants Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) on Thursday, pledging to make blockbuster weight-loss drugs like Zepbound and Wegovy significantly cheaper and accessible for millions of Americans.

Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility

Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility

‘We’re here to invest,’ says Darius Hughes as he calls comments by other pharma companies ‘a little harsh’

The Guardian - UK

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO

Eli Lilly and Co. (NYSE:LLY) CEO Dave Ricks strongly criticized the United Kingdom's approach to drug pricing, describing it as "probably the worst country in Europe" for pharmaceutical prices.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Mounjaro manufacturer blasts UK as ‘worst country in Europe’ for drug prices

The boss of Eli Lilly, Dave Ricks, warns that Britain will miss out on new drugs as a result of pricing issues

The Independent UK

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

The Guardian - UK

Eli Lilly calls UK ‘worst country in Europe’ for drug prices; gold nears record high - as it happened

Spot gold trading just below Monday’s fresh record high

The Guardian - UK

Eli Lilly Co. Q2 FY2025 Earnings Transcript

Eli Lilly Co. (NYSE:LLY) reported its second-quarter 2025 financial results ahead of the opening bell on Thursday.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

Eli Lilly CEO's explains how failing fast leads to success

Eli Lilly CEO's explains how failing fast leads to success

For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.

How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut

How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

People

154,232 stories

Patrick Vallance

Stéphane Bancel

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

Leadership Next

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

322,963 stories

127,158 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play